DK0910659T3 - Antistoffer mod et kompleks af CD4 og et kemokin-receptordomæne og anvendelse deraf mod HIV-infektioner - Google Patents

Antistoffer mod et kompleks af CD4 og et kemokin-receptordomæne og anvendelse deraf mod HIV-infektioner

Info

Publication number
DK0910659T3
DK0910659T3 DK97926870T DK97926870T DK0910659T3 DK 0910659 T3 DK0910659 T3 DK 0910659T3 DK 97926870 T DK97926870 T DK 97926870T DK 97926870 T DK97926870 T DK 97926870T DK 0910659 T3 DK0910659 T3 DK 0910659T3
Authority
DK
Denmark
Prior art keywords
antibodies
hiv
immunodeficiency virus
directed
primary isolates
Prior art date
Application number
DK97926870T
Other languages
Danish (da)
English (en)
Inventor
Chang Yi Wang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/808,374 external-priority patent/US5961976A/en
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Application granted granted Critical
Publication of DK0910659T3 publication Critical patent/DK0910659T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK97926870T 1996-06-03 1997-06-03 Antistoffer mod et kompleks af CD4 og et kemokin-receptordomæne og anvendelse deraf mod HIV-infektioner DK0910659T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65714996A 1996-06-03 1996-06-03
US08/808,374 US5961976A (en) 1996-06-03 1997-02-28 Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US08/867,149 US5912176A (en) 1996-06-03 1997-06-02 Antibodies against a host cell antigen complex for pre and post exposure protection from infection by HIV

Publications (1)

Publication Number Publication Date
DK0910659T3 true DK0910659T3 (da) 2006-11-27

Family

ID=27417977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97926870T DK0910659T3 (da) 1996-06-03 1997-06-03 Antistoffer mod et kompleks af CD4 og et kemokin-receptordomæne og anvendelse deraf mod HIV-infektioner

Country Status (10)

Country Link
EP (1) EP0910659B1 (de)
JP (1) JP2000511775A (de)
CN (1) CN1227610A (de)
AT (1) ATE335835T1 (de)
BR (1) BRPI9709524B8 (de)
CA (1) CA2256306C (de)
DE (1) DE69736474T2 (de)
DK (1) DK0910659T3 (de)
ES (1) ES2270461T3 (de)
WO (1) WO1997046697A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
WO2000040964A1 (en) * 1999-01-08 2000-07-13 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Inhibition of cd4-ccr5 interaction
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
US8637466B2 (en) 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN102649818B (zh) * 2011-02-25 2014-10-08 厦门大学 抗cd4蛋白的单克隆抗体及其活性片段及用途
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
SMT202000255T1 (it) 2015-03-20 2020-07-08 The United States Of America As Represented By The Secretary Department Of Health And Human Services Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0353894A (ja) * 1989-07-21 1991-03-07 Calpis Food Ind Co Ltd:The 抗ヒトｃｄ４ペプチドに対するモノクローナル抗体
AU6080794A (en) * 1992-12-31 1994-08-15 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
CA2224073A1 (en) * 1995-06-09 1996-12-27 Francisco Veas Means for detecting and preventing hiv infection involving use of receptors or binding sites capable of interacting with gp120
EP0915969A4 (de) * 1996-04-02 2002-04-17 Progenics Pharm Inc Unterdrückung der infektion von cd4+ zellen durch hiv

Also Published As

Publication number Publication date
BRPI9709524B8 (pt) 2021-05-25
DE69736474D1 (de) 2006-09-21
ATE335835T1 (de) 2006-09-15
CA2256306A1 (en) 1997-12-11
EP0910659B1 (de) 2006-08-09
WO1997046697A2 (en) 1997-12-11
EP0910659A2 (de) 1999-04-28
JP2000511775A (ja) 2000-09-12
WO1997046697A3 (en) 1997-12-11
BR9709524A (pt) 2000-05-09
ES2270461T3 (es) 2007-04-01
DE69736474T2 (de) 2007-01-18
BRPI9709524B1 (pt) 2016-11-01
CA2256306C (en) 2011-03-29
CN1227610A (zh) 1999-09-01

Similar Documents

Publication Publication Date Title
Bures et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa
WO1997046697A3 (en) Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
Sullivan et al. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization
Ferrari et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum
Cecilia et al. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
Sattentau et al. The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule
JP2755395B2 (ja) Ｈｉｖ感染細胞に殺作用する抗体異種結合体
Dettenhofer et al. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions
Bastiani et al. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions
DK0479909T3 (da) Bispecifikke reagenser til AIDS-behandling
EP0675904A4 (de) Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch.
ATE405679T1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
Beddows et al. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
ATE238420T1 (de) Rekombinanter humanisierter antikörper gegen menschlichen immunschwächevirus
Nakowitsch et al. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies
Wang et al. Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex
Martinez-A et al. Immunological consequences of HIV infection: advantage of being low responder casts doubts on vaccine development
Fujita et al. Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif
Jagodzinski et al. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes
Tanabe-Tochikura et al. Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro
Pal et al. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A
WO1995007716A1 (en) Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
Chen et al. HIV-1 gp41 selectively inhibits spontaneous cell proliferation of human cell lines and mitogen-and recall antigen-induced lymphocyte proliferation